Amidst worries about a third COVID-19 wave and emerging coronavirus variants, there’s a lot of good news from Italy: 2 clinical trials have started on the same day.
On March 1, Takis and Rottapharm Biotech announced the start of the clinical trial of COVID-eVax, their jointly developed vaccine candidate. "The start of the clinical trials represents an important step in the development of DNA technology against COVID-19 but also for other diseases", says Luigi Aurisicchio, CEO and scientific director of Takis.
But that is not all, AchilleS Vaccines, that was granted financing in June by the EU Malaria Fund, together with Toscana Life Sciences (trial sponsor) and Cross Alliance (a CRO) is managing clinical trial sites on Monday for their monoclonal antibody, mAbCo19. “Within a bit more than six months we’ve been able, with the support of an outstanding team, to transform a patent into a product which is quite an unbelievable outcome”, says Riccardo Baccheschi, CEO and president of AchilleS Vaccines. “The aim is now reached; the product is there.”
Click here
to continue reading.